Institute of Basic Medical Sciences, National Cheng Kung University, Tainan, Taiwan.
Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan.
J Biomed Sci. 2018 Apr 24;25(1):38. doi: 10.1186/s12929-018-0439-z.
Millions of people around the world suffer from bone disorders, likes osteoporosis, rheumatoid arthritis (RA), and cancer-induced osteolysis. In general, the bone remodeling balance is determined by osteoclasts and osteoblasts, respectively responsible for bone resorption and bone formation. Excessive inflammation disturbs the activities of these two kinds of cells, typically resulting in the bone loss.
IL-20 is emerging as a potent angiogenic, chemotactic, and proinflammatory cytokine related to several chronic inflammatory disorders likes psoriasis, atherosclerosis, cancer, liver fibrosis, and RA. IL-20 has an important role in the regulation of osteoclastogenesis and osteoblastogenesis and is upregulated in several bone-related diseases. The anti-IL-20 monoclonal antibody treatment has a therapeutic potential in several experimental disease models including ovariectomy-induced osteoporosis, cancer-induced osteolysis, and bone fracture.
This review article provides an overview describing the IL-20's biological functions in the common bone disorders and thus providing a novel therapeutic strategy in the future.
全世界数百万人患有骨骼疾病，如骨质疏松症、类风湿关节炎（RA）和癌症引起的溶骨性骨病。一般来说，骨重塑平衡由破骨细胞和成骨细胞决定，分别负责骨吸收和骨形成。过度的炎症会干扰这两种细胞的活动，通常导致骨丢失。
IL-20 是一种新型的促血管生成、趋化和促炎细胞因子，与几种慢性炎症性疾病有关，如银屑病、动脉粥样硬化、癌症、肝纤维化和 RA。IL-20 在破骨细胞生成和成骨细胞生成的调节中起重要作用，并在几种与骨骼相关的疾病中上调。抗 IL-20 单克隆抗体治疗在几种实验疾病模型中具有治疗潜力，包括去卵巢诱导的骨质疏松症、癌症诱导的溶骨性骨病和骨折。
本文综述了 IL-20 在常见骨骼疾病中的生物学功能，为未来提供了一种新的治疗策略。
